The Priority Review

Tag

Immunotherapy

1 story

  1. Approvals

    FDA approves Voceryq for adults with recurrent respiratory papillomatosis

    Seven of 26 adults with at least three baseline surgeries (27%) needed no surgery in the first year after Voceryq, the FDA said in granting accelerated approval. Adults with recurrent respiratory papillomatosis now have a plasmid DNA-based immunotherapy approved in the U.S.